We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.51B
1-Year Est. Return
164.17%
This Fund
S&P 500
This Quarter
Est. Return
+50.7%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$1.36B
AUM Growth
+$330M
(+32%)
Cap. Flow
-$51.5M
Cap. Flow
% of AUM
-3.79%
Top 10 Holdings %
Top 10 Hldgs %
77.83%
Holding
43
New
3
Increased
11
Reduced
10
Closed
9
Top Buys
| 1 |
Nurix Therapeutics
NRIX
|
+$63.4M |
| 2 |
Scholar Rock
SRRK
|
+$49.4M |
| 3 |
Annexon
ANNX
|
+$14.3M |
| 4 |
Immunome
IMNM
|
+$12.2M |
| 5 |
RAPT
RAPT Therapeutics
RAPT
|
+$10.4M |
Top Sells
| 1 |
Zymeworks
ZYME
|
+$70.1M |
| 2 |
LivaNova
LIVN
|
+$46.2M |
| 3 |
AKRO
Akero Therapeutics
AKRO
|
+$35.5M |
| 4 |
Cogent Biosciences
COGT
|
+$21.7M |
| 5 |
ETNB
89bio
ETNB
|
+$21.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Scholar Rock
SRRK
$6.46B
| $230M | 16.94% |
5,220,846
+1,316,390
| +34% | +$49.4M |
|
2
Krystal Biotech
KRYS
$10.2B
| $167M | 12.3% |
677,705
+16,317
| +2% | +$3.43M |
|
|
3
Nurix Therapeutics
NRIX
$2.45B
| $154M | 11.31% |
8,093,908
+4,415,514
| +120% | +$63.4M |
|
4
Stoke Therapeutics
STOK
$1.83B
| $128M | 9.43% |
4,034,070
-141,472
| -3% | -$4.25M |
|
|
5
Immunome
IMNM
$2.53B
| $123M | 9.05% |
5,718,385
+695,000
| +14% | +$12.2M |
|
6
Regenxbio
RGNX
$621M
| $62.9M | 4.63% |
4,368,804
-324,585
| -7% | -$4.05M |
|
7
ADC Therapeutics
ADCT
$156M
| $55.3M | 4.07% |
15,666,731
| – | – |
|
|
8
Cogent Biosciences
COGT
$6.67B
| $51.1M | 3.76% |
1,437,918
-771,200
| -35% | -$21.7M |
|
|
9
Annexon
ANNX
$931M
| $50.5M | 3.72% |
10,050,644
+3,750,000
| +60% | +$14.3M |
|
10
Beam Therapeutics
BEAM
$3.12B
| $35.6M | 2.62% |
1,285,859
-101,700
| -7% | -$2.59M |
|
11
Neurogene
NGNE
$779M
| $30.1M | 2.21% |
1,459,599
+160,577
| +12% | +$4M |
|
|
RAPT
12
DELISTED
RAPT Therapeutics
RAPT
| $30M | 2.21% |
885,927
+333,333
| +60% | +$10.4M |
|
13
Absci
ABSI
$1.66B
| $28.8M | 2.12% |
8,253,316
| – | – |
|
14
Nuvation Bio
NUVB
$2.02B
| $28.3M | 2.09% |
3,163,256
+132,247
| +4% | +$819K |
|
15
IDEAYA Biosciences
IDYA
$3.54B
| $25.7M | 1.89% |
742,017
| – | – |
|
16
Shattuck Labs
STTK
$605M
| $20.2M | 1.49% |
5,539,724
| – | – |
|
|
SLN
17
Silence Therapeutics
SLN
$487M
| $13.2M | 0.97% |
2,164,777
| – | – |
|
|
18
Zymeworks
ZYME
$1.81B
| $12.9M | 0.95% |
491,654
-3,214,096
| -87% | -$70.1M |
|
19
Fate Therapeutics
FATE
$336M
| $12.6M | 0.93% |
12,872,946
| – | – |
|
20
Replimune Group
REPL
$824M
| $10.7M | 0.79% |
1,099,756
+563,938
| +105% | +$4.79M |
|
|
DBVT
21
DBV Technologies
DBVT
$917M
| $10.5M | 0.78% |
+549,840
| New | +$8.59M |
|
22
Solid Biosciences
SLDB
$928M
| $10.5M | 0.77% |
1,860,542
-38,800
| -2% | -$210K |
|
|
CBLL
23
CeriBell Inc
CBLL
$741M
| $9.54M | 0.7% |
435,239
| – | – |
|
24
Establishment Labs
ESTA
$2.63B
| $8.21M | 0.6% |
112,664
-16,700
| -13% | -$1.01M |
|
25
Atara Biotherapeutics
ATRA
$76.6M
| $7.99M | 0.59% |
441,701
| – | – |
|
Similar funds
ORI
GAI
HCMG
FMI
FCM
PP
AM
BFO